DICE Stock Overview
DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
DICE Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$31.79 |
| 52 Week High | US$45.99 |
| 52 Week Low | US$12.64 |
| Beta | 0 |
| 1 Month Change | 1.47% |
| 3 Month Change | -5.05% |
| 1 Year Change | 81.76% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -13.82% |
Recent News & Updates
DICE Therapeutics positive phase 1 data for psoriasis candidate leads shares 71% higher
Oct 11Here's Why We're Not Too Worried About DICE Therapeutics' (NASDAQ:DICE) Cash Burn Situation
Sep 11
DICE Therapeutics GAAP EPS of -$0.58
Aug 11Recent updates
DICE Therapeutics positive phase 1 data for psoriasis candidate leads shares 71% higher
Oct 11Here's Why We're Not Too Worried About DICE Therapeutics' (NASDAQ:DICE) Cash Burn Situation
Sep 11DICE Therapeutics GAAP EPS of -$0.58
Aug 11DICE Therapeutics initiated at buy at Wainwright on platform for small molecule drugs
Jul 18Shareholder Returns
| DICE | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -0.06% | -1.0% | 1.7% |
| 1Y | 81.8% | 4.6% | -9.1% |
Return vs Industry: DICE exceeded the US Pharmaceuticals industry which returned 3.2% over the past year.
Return vs Market: DICE exceeded the US Market which returned -12.5% over the past year.
Price Volatility
| DICE volatility | |
|---|---|
| DICE Average Weekly Movement | 6.0% |
| Pharmaceuticals Industry Average Movement | 11.7% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: DICE is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: DICE's weekly volatility has decreased from 13% to 6% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 65 | J. Judice | https://www.dicemolecules.com |
DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE, is designed to discover selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. The company’s lead therapeutic candidate is DC-806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17, which is a validated drug target implicated in a various immunology indications.
DICE Therapeutics, Inc. Fundamentals Summary
| DICE fundamental statistics | |
|---|---|
| Market Cap | US$1.52b |
| Earnings (TTM) | -US$76.86m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-19.7x
P/E RatioIs DICE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DICE income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$33.88m |
| Gross Profit | -US$33.88m |
| Other Expenses | US$42.98m |
| Earnings | -US$76.86m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.61 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did DICE perform over the long term?
See historical performance and comparison